Cara Therapeutics discontinues study on a neurological condition as drug fails

Tvardi Therapeutics

12/06/2024 21:16

June 12 (Reuters) - Cara Therapeutics  CARA.O  said on
Wednesday it will discontinue a mid-to-late stage study for a
neurological condition that causes itching after its
experimental drug did not demonstrate a meaningful clinical
benefit compared to placebo.

 (Reporting by Puyaan Singh in Bengaluru; Editing by Alan
Barona)
 ((Puyaan.Singh@thomsonreuters.com;))